Ann: Appendix 4C - Quarterly - 30 September 2023, page-6

"Following this meeting, the Company has engaged with several global pharmaceutical and biotechnology companies who are interested in Patrys’ deoxymab technology for applications ranging from cancer therapies through to the cellular and nuclear delivery of therapeutic payloads. These discussion are ongoing. ""

I hope that Merck is one of the interested parties -
Merck, flush with Keytruda cash and eyeing the loss of exclusivity on its megablockbuster, has agreed to pay $4 billion upfront to co-develop and co-commercialize three Daiichi ADCs. The numbers past that point rise to eye-watering levels. Merck has committed to $1.5 billion in continuation payments over the next 24 months and up to $16.5 billion in sales milestones.

Link to article below -

Merck pays $4B for Daiichi ADCs in bet on post-Keytruda future (fiercebiotech.com)